摘要
目的探讨沙美特罗氟替卡松治疗哮喘的临床疗效及对肺功能的影响。方法将120例哮喘患者随机分为对照组与观察组,每组60例。给予观察组患者沙美特罗氟替卡松吸入,对照组患者接受沙丁胺醇吸入。比较两组临床治疗总有效率、日间哮喘症状评分及治疗前后肺功能的改变。结果观察组与对照组治疗总有效率分别为91.7%和78.3%,差别具有统计学意义(P<0.05);治疗后1月～3月,观察组患者日间哮喘症状评分显著低于对照组(P<0.05);治疗后3月观察组用力肺活量(FVC)、第一秒末用力呼气量(FEV1)实/预、最大呼气流速(PEF)和最大呼气中段流量(MMEF)显著优于对照组(P<0.05)。结论沙美特罗氟替卡松治疗哮喘可显著提高临床疗效,改善患者肺功能及预后。
Objective To explore the clinical efficacy of salmeterol and fluticasone in the treatment of asthma and its influence on pulmonary function. Methods 120 patients with asthma were randomly and evenly divided into the control group and the experience group. The experience group were given salmeterol and fluticasone treatment and the control group were given salbutamol inhalation. The effective rates, frequency of diurnal asthmatic attacks and the change of pulmonary function were compared between the two groups before and after the treatment. Results The effective rates were 91.7% and 78.3% respectively in the experience group and in the control group with significant difference （P 〈 0.05 ）. The frequency of diurnal asthmatic attacks in the experience group were much lower than that in the control group （ P 〈 0. 05 ）. Besides, the improvement of IWC, FEV1 , PEF and MMEF after the treatment were more pronounced in the experience group than in the control group （ P 〈 0. 05 ）. Conclusions The treatment of salmeterol and fluticasone is an effective way for patients with asthma that can improve the clinical efficacy, pulmonary function and prognosis.
出处
《临床肺科杂志》
2013年第1期55-56,共2页
Journal of Clinical Pulmonary Medicine
